Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Up 12.0% in December

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,120,000 shares, an increase of 12.0% from the November 30th total of 4,570,000 shares. Approximately 9.3% of the shares of the company are sold short. Based on an average trading volume of 805,900 shares, the days-to-cover ratio is currently 6.4 days.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded down $0.37 during mid-day trading on Monday, reaching $33.03. The company had a trading volume of 682,488 shares, compared to its average volume of 733,205. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of 2.91 and a beta of 0.80. The business's 50-day simple moving average is $48.89 and its 200 day simple moving average is $46.16. Agios Pharmaceuticals has a one year low of $20.96 and a one year high of $62.58.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the second quarter worth $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 363 shares during the last quarter. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the third quarter valued at about $146,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Raymond James restated an "outperform" rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Royal Bank of Canada increased their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, December 9th. Finally, Leerink Partners lowered shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of "Hold" and a consensus target price of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.